Spironolactone Tablet, Film Coated
Product Images NDC 71335-0053

4 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 71335-0053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl713350053)

Label Image (Lbl713350053)
Label for Spironolactone 25 mg Tablet, film-coated, oral dosage form, packaged by Bryant Ranch Prepack in Burbank, CA. The label compares this product to Aldactone 25 mg Tablet by Intas Pharmaceuticals Limited. It indicates a package count of 30 tablets and storage instructions at 20°-25°C (68°-77°F). The product NDC shown is 71335-0053-1.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A Kaplan-Meier survival curve comparing the probability of an event over time in months for two groups: one treated with spironolactone and the other with placebo. The graph shows higher survival probability in the spironolactone group with a significant log-rank p-value less than 0.001.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot chart depicting hazard ratios (HR) and 95% confidence intervals (CI) for subgroups in a clinical study comparing Spironolactone versus placebo. Subgroups include age, sex, race, LVEF %, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin, ACE inhibitor, and beta blocker use. The chart visually indicates whether Spironolactone or placebo is favored across these groups.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure diagram of spironolactone, illustrating its molecular arrangement with labeled carbon rings, ketone groups, and sulfur-containing functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.